PMID- 10587357
OWN - NLM
STAT- MEDLINE
DCOM- 20000113
LR  - 20220330
IS  - 0022-1007 (Print)
IS  - 1540-9538 (Electronic)
IS  - 0022-1007 (Linking)
VI  - 190
IP  - 11
DP  - 1999 Dec 6
TI  - Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells 
      expands specific cytotoxic T cells and induces regression of some metastases in 
      advanced stage IV melanoma.
PG  - 1669-78
AB  - Dendritic cells (DCs) are considered to be promising adjuvants for inducing 
      immunity to cancer. We used mature, monocyte-derived DCs to elicit resistance to 
      malignant melanoma. The DCs were pulsed with Mage-3A1 tumor peptide and a recall 
      antigen, tetanus toxoid or tuberculin. 11 far advanced stage IV melanoma 
      patients, who were progressive despite standard chemotherapy, received five DC 
      vaccinations at 14-d intervals. The first three vaccinations were administered 
      into the skin, 3 x 10(6) DCs each subcutaneously and intradermally, followed by 
      two intravenous injections of 6 x 10(6) and 12 x 10(6) DCs, respectively. Only 
      minor (less than or equal to grade II) side effects were observed. Immunity to 
      the recall antigen was boosted. Significant expansions of Mage-3A1-specific 
      CD8(+) cytotoxic T lymphocyte (CTL) precursors were induced in 8/11 patients. 
      Curiously, these immune responses often declined after the intravenous 
      vaccinations. Regressions of individual metastases (skin, lymph node, lung, and 
      liver) were evident in 6/11 patients. Resolution of skin metastases in two of the 
      patients was accompanied by erythema and CD8(+) T cell infiltration, whereas 
      nonregressing lesions lacked CD8(+) T cells as well as Mage-3 mRNA expression. 
      This study proves the principle that DC "vaccines" can frequently expand 
      tumor-specific CTLs and elicit regressions even in advanced cancer and, in 
      addition, provides evidence for an active CD8(+) CTL-tumor cell interaction in 
      situ as well as escape by lack of tumor antigen expression.
FAU - Thurner, B
AU  - Thurner B
AD  - Department of Dermatology, University of Erlangen-Nuremberg, D-91052 Erlangen, 
      Germany.
FAU - Haendle, I
AU  - Haendle I
FAU - Roder, C
AU  - Roder C
FAU - Dieckmann, D
AU  - Dieckmann D
FAU - Keikavoussi, P
AU  - Keikavoussi P
FAU - Jonuleit, H
AU  - Jonuleit H
FAU - Bender, A
AU  - Bender A
FAU - Maczek, C
AU  - Maczek C
FAU - Schreiner, D
AU  - Schreiner D
FAU - von den Driesch, P
AU  - von den Driesch P
FAU - Brocker, E B
AU  - Brocker EB
FAU - Steinman, R M
AU  - Steinman RM
FAU - Enk, A
AU  - Enk A
FAU - Kampgen, E
AU  - Kampgen E
FAU - Schuler, G
AU  - Schuler G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (MAGEA3 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Tetanus Toxoid)
RN  - 0 (Tuberculin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, Neoplasm/immunology
MH  - CD8-Positive T-Lymphocytes/immunology/pathology
MH  - *Cancer Vaccines
MH  - Dendritic Cells/*immunology/*transplantation
MH  - Female
MH  - Humans
MH  - Immunization Schedule
MH  - Lung Neoplasms/*secondary/therapy
MH  - Lymphocytes, Tumor-Infiltrating/immunology/pathology
MH  - Male
MH  - Melanoma/*immunology/pathology/*therapy
MH  - Middle Aged
MH  - Monocytes/immunology
MH  - Neoplasm Metastasis
MH  - Neoplasm Proteins/*immunology
MH  - Neoplasm Staging
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tetanus Toxoid/immunology
MH  - Tuberculin/immunology
PMC - PMC2195739
EDAT- 1999/12/10 00:00
MHDA- 1999/12/10 00:01
PMCR- 2000/06/06
CRDT- 1999/12/10 00:00
PHST- 1999/12/10 00:00 [pubmed]
PHST- 1999/12/10 00:01 [medline]
PHST- 1999/12/10 00:00 [entrez]
PHST- 2000/06/06 00:00 [pmc-release]
AID - 99-0918 [pii]
AID - 10.1084/jem.190.11.1669 [doi]
PST - ppublish
SO  - J Exp Med. 1999 Dec 6;190(11):1669-78. doi: 10.1084/jem.190.11.1669.